Joseph D. Keegan - 20 Aug 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
20 Aug 2026, 17:02:57 UTC
Prior SEC filing
03 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ JOSEPH D KEEGAN

Key filing fact

Joseph D. Keegan filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 20 Aug 2026.

Key facts

  • This page summarizes Joseph D. Keegan's Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 20 Aug 2026, 17:02.

Change

  • Previous filing in this sequence was filed on 03 Nov 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001260556 Primary reporting owner

KEEGAN JOSEPH D

Relationship
Director
Address
C/O INTERPACE BIOSCIENCES, INC., 2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310, PARSIPPANY
Signature
/s/ JOSEPH D KEEGAN
Signature date
20 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXG transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares
+69,252
Change %
Price
$0.000000*
Shares after
69,252
Date
20 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
69,252
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

Footnote F2

The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .